CS-2701

生物活性体外研究体内研究 CS-2701 试剂级价格

CS-2701

CAS号:289483-69-8
英文名:E-7820
中文名:CS-2701
CBNumber:CB61011214
分子式:C17H12N4O2S
分子量:336.37
MOL File:289483-69-8.mol

CS-2701化学性质

沸点 :626.2±65.0 °C(Predicted)
密度 :1.48±0.1 g/cm3(Predicted)
储存条件 :Store at -20°C
溶解度 :DMSO:67.0(Max Conc. mg/mL);199.19(Max Conc. mM)
形态 :A crystalline solid
酸度系数(pKa) :8.17±0.30(Predicted)
颜色 :Light yellow to light brown

CS-2701性质、用途与生产工艺

生物活性 E7820是独特的血管生成抑制剂，具有抗肿瘤活性。
体外研究

E7820 (ER68203-00) inhibits both bFGF- and VEGF-driven ube formation of human umbilical vascular endothelial cell (HUVEC) in a dose-dependent manner with IC ₅₀ of 0.20 and 0.24 μg/ml, respectively.
E7820 inhibits proliferation of HUVEC induced by either bFGF or VEGF in serum-free medium (SFM). The IC ₅₀ values are 0.10 and 0.081 μg/ml, respectively. Antiproliferative activity of E7820 against both WiDr and LoVo cells is very weak compared with that against HUVEC. The values of IC50 were 29 and 15 μg/ml, respectively.

体内研究

E7820 (ER68203-00) (50-200 mg/kg; p.o. ; twice daily for 14 days) delays the growth of WiDr cells inoculated s.c..
E7820 (200-400 mg/kg; p.o.;once daily for 4 days) potently inhibits WiDr-induced angiogenesis.

Animal Model:	Six-week-old female nude mice (KSN mice, WiDr-induced angiogenesis model)
Dosage:	50, 100, 200 mg/kg
Administration:	p.o. ; twice daily for 14 days from 2 days after inoculation of the tumor cells
Result:	The antitumor effect was dose-dependent at 50, 100, and 200 mg/kg, and the tumor growth rates were 52%, 46%, and 27%, respectively.